EBMT 2021 | Optimizing outcomes with pre- and post-transplant interventions
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares an overview of his talk on the optimization of pre-and post-transplant interventions at EBMT 2021. Allogeneic stem cell transplantation (allo-SCT) remains the only curative approach in many hematological malignancies, however, allo-SCT alone may not be sufficient, and post-transplant consolidation and maintenance may be required. Prof. Mohty discusses how disease-control prior to transplant and post-transplant are key to preventing disease recurrence, highlighting evidence from patients with FLT3-ITD acute myeloid leukemia treated with FLT3 inhibitors post-transplant. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
